<DOC>
	<DOCNO>NCT01858532</DOCNO>
	<brief_summary>This study conduct evaluate effect Atrasentan Renal Outcomes Subjects Type 2 Diabetes Nephropathy .</brief_summary>
	<brief_title>Study Of Diabetic Nephropathy With Atrasentan</brief_title>
	<detailed_description>The study objective evaluate effect atrasentan compare placebo time double serum creatinine onset end stage renal disease ( ESRD ) subject type 2 diabetes nephropathy treat maximum tolerated label daily dose ( MTLDD ) Renin Angiotensin System ( RAS ) inhibitor . In addition , study assess effect atrasentan compare placebo cardiovascular morbidity mortality , urine albumin excretion , change estimate glomerular filtration rate ( eGFR ) , well impact quality life subject type 2 diabetes nephropathy .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>Subject type 2 diabetes ( include patient latent autoimmune diabetes insulintreated patient without history diabetic ketoacidosis also negative antiglutamic acid decarboxylase test AND elevate postprandial serum Cpeptide level ) treat least one antihyperglycemic medication ACEi/or ARB ( RAS inhibitor ) least 4 week prior Screening S2 visit . For entry RunIn Period subject must satisfy follow criterion base Screening laboratory value : Estimated glomerular filtration rate ( eGFR ) 25 75 mL/min/1.73 m2 urine albumin creatinine ratio ( UACR ) great equal 300 less 5,000 mg/g ( great equal 34 mg/mmol less 565 mg/mmol ) ; Serum albumin great equal 2.5 g/dL ( 25 g/L ) ; Brain natriuretic peptide ( BNP ) less equal 200 pg/mL ( 200 ng/L ) ; Systolic blood pressure ( SBP ) great equal 110 less equal 180 mmHg ; Serum Potassium great equal 3.5 mEq/L ( 3.5 mmol/L ) less equal 6.0 mEq/L ( 6.0 mmol/L ) ; Subjects maximum tolerated label daily dose ( MTLDD ) RAS inhibitor great equal 4 week diuretic time screen satisfy criterion may proceed last visit RunIn Period ( R6 ) ; Subjects already MTLDD RAS inhibitor great equal 4 week diuretic ( unless medically contraindicate ) time Screening start diuretic proceed RunIn least 2 week . For entry Enrichment Period subject must satisfy follow criterion base last visit RunIn Period : RAS inhibitor MTLDD previous 4 week adjustment dose ; Subjects MTLDD RAS inhibitor diuretic ( unless medically contraindicate ) time Screening must RunIn least 2 week . For entry DoubleBlind Treatment Period , subject must satisfy follow criterion base last visit Enrichment Period : RAS inhibitor MTLDD previous 6 week Enrichment Period adjustment dose ; Diuretic dose unless medically contraindicate clinically intolerable investigator 's judgement ( i.e. , hypotension hypokalemia ) ; Subject must weight change great equal 3 kg begin Enrichment end Enrichment Period absolute serum BNP great equal 300 pg/mL ( 300 ng/L ) last Enrichment visit ; Subject must increase serum creatinine great 0.5 mg/dL great 20 % increase begin Enrichment end Enrichment Period . Subject history severe peripheral edema facial edema require diuretic unrelated trauma history myxedema prior 4 week initial Screening S1 visit . Subject history pulmonary hypertension , pulmonary fibrosis lung diseases require oxygen therapy ( e.g. , chronic obstructive pulmonary disease , emphysema ) . Subject documented diagnosis heart failure , previous hospitalization heart failure current constellation symptom ( dyspnea exertion , pedal edema , orthopnea , paroxysmal nocturnal dyspnea ) felt compatible heart failure , explain cause , change medication management direct heart failure . Subject know nondiabetic kidney disease ( kidney stone ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Nephropathy</keyword>
</DOC>